40 results about "Hepatic ischemia" patented technology

The invention discloses a gene Mindin and an application of an inhibitor thereof in a hepatic ischemia reperfusion injury, and belongs to the field of functions and applications of genes. After the experiment is carried out through a hepatic ischemia reperfusion injury model by taking a gene Mindin knockout rat and a Mindin transgenosis rat with a hepatic cell specificity as experimental subjects, the result shows that the hepatic necrosis of the gene Mindin knockout rat is obviously inhibited and the hepatic function of the gene Mindin knockout rat is obviously improved in comparison with a wild-type C57 rat, but the hepatic necrosis of the Mindin transgenosis rat with the hepatic cell specificity is obviously increased and the hepatic function of the hepatic necrosis Mindin transgenosis rat is seriously deteriorated. Thus, the gene Mindin has a function of deteriorating hepatic cells, especially, the gene Mindin has the function of deteriorating the hepatic ischemia reperfusion injury. Aiming at the function of the gene Mindin, the gene Mindin can serve as a medicine target for screening medicines for treating the hepatic ischemia reperfusion injury. The inhibitor of the gene Mindin can be used for preparing the medicines for treating the hepatic ischemia reperfusion injury.

The invention provides a penthorum chinense pursh extract. The HPLC finger-print is characterized by comprising four characteristic peaks, wherein the retention time of the first peak is 10.4+/-0.25 min, and the peak area of the first peak is 1682000+/-8000; the retention time of the second peak is 12.5+/-0.25 min, and the peak area of the second peak is 36750+/-700; the retention time of the third peak is 13.0+/-0.25 min, and the peak area of the third peak is 2461000+/-3000; the retention time of the fourth peak is 14.9+/-0.25 min, and the peak area of the fourth peak is 1831000+/-5000. The treatment effect of the penthorum chinense pursh extract is excellent in treating hepatic ischemia reperfusion liver injuries and chemical liver injuries and has broad clinical application prospects.

The invention provides an application of pinocembrin dihydrogen chalcone-7-O-[3'-O-galloyl-4',6'-hexahydroxydiphenodicarboxy]-beta-D-glucoside in preparation of a liver protection medicine. The penthorum chinense pursh macrocyclic polyphenol monomer namely pinocembrin dihydrogen chalcone-7-O-[3'-O-galloyl-4',6'-hexahydroxydiphenodicarboxy]-beta-D-glucoside has a liver protection effect, can be used for preventing and treating liver injuries, and has a definite curative effect on hepatic ischemia-reperfusion injuries and chronic liver injuries, and the effect is superior to that of positive medicine namely Gansu Granules, so that the penthorum chinense pursh macrocyclic polyphenol monomer can be used for replacing the Gansu Granules and has a good clinical application prospect.

The invention discloses application of Mincle and an inhibitor thereof in hepatic ischemia reperfusion injuries, and belongs to the function and application field of genes. A hepatic cell specific Mincle gene knockout mouse and a Mincle transgenic mouse as experimental subjects, the functions of a Mincle gene are researched by virtue of a hepatic ischemia reperfusion injury model, and the Mincle gene is discovered to have an effect of exacerbating liver functions, so that the Mincle has the following applications: application of the Mincle serving as a drug target in screening medicines for preventing, relieving and/or treating the hepatic ischemia reperfusion injuries or protecting the liver functions, wherein screening the medicines for preventing, relieving and/or treating the hepatic ischemia reperfusion injuries or protecting the liver functions refers to screening the medicines capable of inhibiting Mincle expression, and application of the inhibitor of the Mincle in preparation of the medicines for preventing, relieving and/or treating the hepatic ischemia reperfusion injuries or protecting the liver functions.

The invention discloses a polypeptide substance, preparation method and application thereof. The invention also discloses extraction process of two polypeptides, and determines molecular weight and amino acid sequence of the polypeptides. The polypeptides are synthesized by the chemical method, and purity analysis and molecular weight measurement results of the polypeptides indicate that molecular ion peak (m/z) completely satisfies theoretical molecular weight. Amino acid analysis result of the polypeptides indicates that amino acid content and the composition of the peptides are in accordance with theoretical values. Amino acid sequence measurement result of the polypeptides indicates primary structure thereof is in accordance with the designed sequence. At the same time, activity measurement result of the polypeptides indicates that the two peptides have activity, and remarkable effect on the treatment of myocardial ischemia, cerebral ischemia, and hepatic ischemia.

The invention provides a liver perfusate, which is prepared by 5,500 to 6,500 mg/L of sodium chloride, 250 to 350 mg/L of potassium chloride, 150 to 250 mg/L of calcium chloride, 3,000 to 3,200 mg/L of sodium lactate, 4 to 6 mmol/L of 1, 6-diphosphofructose, 5 to 15 mg/L of dexamethasone, 2.5 to 3.5 mmol/L of reduced glutathione, and 4 to 6mg/L of verapamil. The product has a simple formula, convenient configuration, low cost and proper potassium concentration, can be safely used for the preservation of isolated organs, more importantly can be applied to the perfusion protection of in vivo organs, and can effectively prevent the injury of hepatic ischemia reperfusion. The invention also provides two preparation methods for the liver perfusate.

The invention discloses application of an inhibitor of TRAF1 (TNF Receptor Associated Factor 1) to liver ischemic disease, belonging to the field of biomedicines. A TRAF1 gene knock-out mouse and a hepatocyte specific TRAF1 transgenic mouse are taken as experimental objects, and a hepatic ischemia reperfusion injury model is adopted. As proved by a result, the hepatic necrosis of the TRAF1 gene knock-out mouse is inhibited remarkably and the liver function is improved remarkably in comparison to those of a wild C57 mouse while the hepatic necrosis of the hepatocyte specific TRAF1 transgenic mouse is increased remarkably and the liver function deteriorates remarkably. Thus, the TRAF1 gene has the effect of deteriorating the liver function, and can particularly deteriorate liver ischemic disease. Aiming at the functions of the TRAF1, application of the TRAF1 as a medicinal target in treatment of liver ischemic disease to the preparation of medicaments for treating liver ischemic disease is provided.

The invention discloses an application of USP10 in hepatic ischemia reperfusion injury. A USP10 gene knockout mouse and a C57BL/6 wild type mouse are selected as experimental subjects, mouse hepatic ischemia reperfusion injury models are constructed respectively, the function of USP10 in hepatic ischemia reperfusion injury is researched, the new function of the USP10 gene in hepatic ischemia reperfusion injury is found, and the application of the USP10 gene in hepatic ischemia reperfusion injury is developed. The over-expression of the USP10 can relieve the hepatic ischemia reperfusion injury by inhibiting inflammation and cell apoptosis, so that the USP10 can be applied to the preparation of the medicine for preventing/treating the hepatic ischemia reperfusion injury, and a new medicine target is provided for the hepatic ischemia reperfusion injury.

The present disclosure provides a method of treating or preventing hepatic ischemia and reperfusion injury in an animal comprising administering an effective amount of an FGL2-FcγRIIB inhibitor to an animal in need thereof. Also provided herein are uses, compositions and screening assays for FGL2- FcγRIIB inhibitors useful in treating hepatic ischemia and reperfusion injury.

The invention discloses a cascaded nano-enzyme as well as a preparation method and application thereof. The cascaded nano-enzyme comprises a metal organic framework carrier, nitric oxide synthetase combined with the metal organic framework carrier and platinum nanoparticles combined with the metal organic framework carrier. The cascaded nano-enzyme belongs to a nano size, has the natural advantage of passive accumulation in the liver compared with a small molecule drug, can increase the enrichment of the drug in the liver, and has higher targeting property. The platinum nanoparticles as the nano-enzyme have excellent reactive oxygen species (ROS) scavenging capacity and can catalyze the reactive oxygen to generate oxygen, the generated oxygen reacts with arginine under the catalysis of nitric oxide synthetase (iNOS) to generate NO in situ, and the bioavailability of NO is improved. Therefore, the cascaded nano-enzyme improves the targeting property and bioavailability of NO, and can simultaneously realize ROS scavenging and NO regulation, thereby realizing effective intervention on injury caused by liver ischemia reperfusion.

Provided is a novel use of ADAMTS13 in the medical field. Use of ADAMTS13 as a biomarker for monitoring the onset of hepatopathy, hepatic ischemia/reperfusion injury or hepatic function after liver transplantation; a method for examining hepatopathy, a method for examining hepatic ischemia/reperfusion injury or a method for examining hepatic function after liver transplantation, each method comprising measuring or monitoring ADAMTS13 activity in a sample obtained from a mammal; and a therapeutic agent for a disease selected from the group consisting of hepatopathy, hepatic ischemia/reperfusioninjury and hepatic dysfunction after liver transplantation, the agent comprising ADAMTS13 or a modification thereof.

The invention discloses application of L-malic acid in preparation of a medicine for preventing and treating liver ischemia-reperfusion injury, and particularly discloses application of the L-malic acid serving as a unique active ingredient in preparation of a medicine or a health care product for preventing or treating the liver ischemia-reperfusion injury. Mouse in-vivo experiments prove that the L-malate can significantly reduce the increase of hepatic injury markers such as alanine aminotransferase, aspartate aminotransferase and lactic dehydrogenase in serum caused by hepatic ischemia/reperfusion, and reduce the hepatic necrosis area; and meanwhile, liver tissue lipid peroxidation and cell ferroptosis caused by ischemia/reperfusion are inhibited, so that hepatic injury is relieved. The invention provides a theoretical basis for treatment of hepatic ischemia/reperfusion injury related diseases, and has clinical application value.